HONG KONG PE BIOSCIENCES LIMITED
PE BIOSCIENCES LTD.
Shanghai Office: Rm. 107, 1/F, 3 Bldg.,
81 North Fute Rd.,
Shanghai Pilot Free Trade Zone, China
|Phone:|| +86-21-6718 1678|
|Phone 2:|| +86-177-0189 6478 (mobile)|
|Phone 3:|| +86-186 1675 9846 (mobile)|
|FAX:|| +86-21-6718 1678|
|E-Mail:||E-Mail this Supplier|
Contact: Sam Zhang
HONG KONG PE BIOSCIENCES LIMITED is a full-service company dedicated to provide qualified peptide related chemicals, proteins and enabling technologies for scientific research. We are serving over 100 customers over North America, Europe , Japan, Korea, Australia Russia, and Latin America. The comprehensive services which assist you on peptides, intermediates manufacturing from the very beginning of pharma research to large scale commercialization, as well as sell , distribute , sourcing peptide related materials and grow your business in China market. We understand that all of the customers have different needs and we strive to provide full services in package and cost-effective solutions.
Proteins and peptides have a significant and rapidly expanding role as medicines, due to their high affinity, specificity, low toxicity, and ability to alter protein–protein interactions. There are currently over 220 widely launched therapeutic proteins and peptides, compared to 64 antibody-derived drugs. The recombinant and synthetic engineering strategies have advanced from those used to generate the first approved molecules such as insulin over 30 years ago. To date, around 100 therapeutic peptides (mostly innovative synthetic ones) are on the market in the USA, Europe and Japan, including those for diagnostics applications. The therapeutic peptide development is growing. In 2011 alone, there were between 500 and 600 peptides in pre-clinical phases. The year 2012 has proven to be another milestone for the peptide pharmaceutical sector, with 5 and 6 peptides meeting market approval respectively in Europe and in the USA. This was the highest number of approvals ever achieved for new biological entities (NBEs) in one year which renders some optimism to the sector. This optimism is confirmed by the statistics, as the regulatory approval rate for peptides is around 20%, versus 10% for small molecules. In addition, the number of peptides per year entering clinical trials has steadily increased from 1 in 1970 to currently around 20. As of April 2012, the clinical pipeline for peptide drugs was composed of 128 peptide candidates. These included 40 in phase I, 74 in phase II and 14 in phase III. In Phase I, the most represented indications are pain (more than 30%), cancer and cardiovascular diseases. In Phase II and III, in which cancer is the leading target (accounting for more than 15% and 40%, respectively), one finds, next to pain and infectious diseases, also indications not much represented in the current market, such as dermatology, allergies, and CNS disorders.
We strive to develop a web-based interface where peptide chemists and biologists around the world can create, share, and modify more cost-effective therapeutic peptides and peptidomimetics.
Product List: 243